Pharmaceutical Development
Provides guidance on the contents of the pharmaceutical development section of a marketing application and introduces Quality by Design (QbD) concepts including Critical Quality Attributes, Critical Process Parameters, and Design Space.
What this does not cover
stated in the document's own scope- Covers development of the drug product; development and manufacture of the drug substance is the subject of ICH Q11.
- Introduces the QbD approach and vocabulary, not the risk-management method used to apply it, which is ICH Q9.
- Describes development and the control strategy, not the ongoing quality system that maintains them — that is ICH Q10.
- Applies to chemical and, in principle, biotechnological products, but does not itself set biologics specifications, which are ICH Q6B.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
ICH Q8(R2) is the harmonised guideline on pharmaceutical development. It describes what the development section of a marketing application should contain and introduces the Quality by Design (QbD) approach — designing quality into a product from an understanding of the science rather than testing it in at the end. It defines the vocabulary the rest of the framework uses: the quality target product profile (QTPP), critical quality attributes (CQAs), critical process parameters (CPPs), and the design space — a multidimensional combination of material attributes and process parameters shown to assure quality, within which movement is not considered a change requiring regulatory approval. The R2 revision incorporated an annex clarifying these QbD concepts.
Scope & applicability
Drug product development across all dosage forms. Primary audience is development scientists and regulatory affairs for submission preparation. Commercial manufacturing teams implement the design space.
Legal basis & how it acquires force
Q8 is an ICH Quality guideline; the R2 version reached Step 4 in August 2009. An ICH guideline is not itself law; regions implement it. The FDA issued Q8(R2) as a guidance for industry, and the EMA adopted it as a scientific guideline in the Common Technical Document framework, with Japan implementing it through MHLW. Q8 is expressly a science-and-risk approach that a sponsor may choose to apply; it describes how development information is presented in Module 3 of the marketing application rather than mandating a single development method.
Document structure
| Part | Covers |
|---|---|
| Components of the drug product | Drug substance, excipients, and their compatibility and function in the formulation |
| Formulation and process development | How the formulation and manufacturing process were developed and understood |
| Quality target product profile and CQAs | Defining the QTPP and identifying the critical quality attributes |
| Critical process parameters and controls | Linking material attributes and process parameters to product quality |
| Design space | Establishing and describing the multidimensional design space and its regulatory meaning |
| Control strategy and lifecycle (Annex) | The QbD annex clarifying control strategy, design space, and continual improvement |
Key requirements
- Identification and justification of Critical Quality Attributes (CQAs)
- Risk-based identification of Critical Process Parameters (CPPs) from QbD studies
- Design space definition — multidimensional combinations of inputs within which quality is assured
- Control strategy linking CQAs and CPPs to manufacturing controls
Implementation tips
- CQA list should flow from development through to commercial batch release specifications
- Design space approved in submission constrains what changes can be made post-approval without filing
Revision notes
R2 issued August 2009 — no revisions since. Core QbD concepts remain current; FDA Process Validation (2011) built upon the Q8 foundation.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Q8 is the "design" leg of the ICH quality trio with Q9 (risk management) and Q10 (quality system). Its QbD vocabulary carries into Q11 for drug substances, and the design-space and established-conditions concepts connect forward to the lifecycle-management tools of ICH Q12. It presents development information in the ICH Common Technical Document that the FDA, EMA, and PMDA all use.
ICH Q8(R2): frequently asked questions
Quick answers to common questions about ICH Q8(R2).
What is a design space in ICH Q8?
The design space is the multidimensional combination and interaction of input variables (such as material attributes) and process parameters that have been demonstrated to provide assurance of quality. Working within an approved design space is not considered a change; moving out of it would normally initiate a regulatory post-approval change.
What does Quality by Design mean under ICH Q8?
It is a systematic approach to development that begins with predefined objectives and emphasises product and process understanding and control, based on sound science and quality risk management — building quality into the product rather than testing it in afterwards.
Is applying QbD mandatory?
No. Q8 describes a science-and-risk approach a sponsor may choose to apply. It sets out how development information is presented in the marketing application; the depth of the QbD approach taken is the applicant’s decision.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.